drugset
drugset / Trial / NCT06177964

Lerapolturev (PVSRIPO) in GBM

NCT06177964 ↗

Phase 2 Recruiting 92 enrolled Darell Bigner Istari Oncology, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this research study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adult patients diagnosed with recurrent glioblastoma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.

Timeline

Start
2024-07-15
Primary completion
2029-02
Completion
2029-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lerapolturev Other / unclassified 2e+08 unknown Other
Comparator Lomustine Small molecule 110 mg/m2 Oral

Indications

glioblastoma